728 / 1084
other subtypes
•
BRCA mutated adenocarcinoma (BRCA1: 1,2% und BRCA2: 3,7%*)
•
ATM deficient adenocarcinoma
•
Small bowel adenocarcinoma harbour PARP-inhibitor-sensitive BRCA-mutations
as well
Institute of Pathology | Alexander Quaas
Gastrointestinal Cancer Group Cologne (GCGC)
*according: Zhen DB, Hruban RH et al, Genet Med 2014
Quaas, A et al.: Pathogenic BRCA mutation in small bowel adenocarcinoma – successfully treatable with the PARP-inhibitor Olaparib, Clin Cancer
Res, 2017 subm.
Kubot, E et al.: Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle 2014
Higuchi T et al. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Cancer Immunol Res. 2015 Nov;3(11):1257-68
für t l ie Prof. Dr. med. Alexander Quaas
PARP-inhibition and Checkpoint-inhibition
(probably) effective in
DNA-repair-deficient
upper GI-
tumors as well